Attached files
| file | filename |
|---|---|
| EX-31.1(B) - EXHIBIT 31.1(B) - DYNASIL CORP OF AMERICA | tv481268_ex31-1b.htm |
| EX-32.1 - EXHIBIT 32.1 - DYNASIL CORP OF AMERICA | tv481268_ex32-1.htm |
| EX-31.1(A) - EXHIBIT 31.1(A) - DYNASIL CORP OF AMERICA | tv481268_ex31-1a.htm |
| EX-23.1 - EXHIBIT 23.1 - DYNASIL CORP OF AMERICA | tv481268_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - DYNASIL CORP OF AMERICA | tv481268_ex21-1.htm |
| 10-K - FORM 10-K - DYNASIL CORP OF AMERICA | tv481268_10k.htm |
Exhibit 99.1
Contact:
Patty Kehe
Dynasil Corporation of America
Phone: 617.668.6855
pkehe@dynasil.com
Dynasil Corporation
of America Reports
Fiscal Year 2017 Financial Results
Newton, MA, December 20, 2017 – Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced earnings attributable to common stockholders of $2.2 million and $0.13 per common share for the fiscal year ended September 30, 2017 and the filing of its Annual Report on Form 10-K.
“For fiscal year 2017, we are
reporting a $1.6 million increase in net income, or $0.09 per common share, for 2017 over the prior year,” said
CEO Peter Sulick. “As our revenue decreased 14% overall in 2017, our positive bottom line results are largely
attributable to a U.S. income tax benefit resulting from the tax deconsolidation of Xcede Technologies, Inc., the
Company’s tissue sealant technology development joint venture.”
“The $6.2 million decrease in revenue resulted from a $4.4 million decrease in revenue in our Optics segment which was largely due to a reduction in orders from production adjustments by two of our largest customers. We anticipate both of these customers to increase their orders in fiscal year 2018. Our Contract Research segment had a $1.8 million, or 9%, decrease in revenue largely from the presidential administration transition during the year. Both contracts awards and funding were significantly delayed during this transitional time. However, these delays were resolved during our fourth quarter and we do not anticipate this situation will reoccur in fiscal year 2018.”
“Despite the decrease in revenue, we have several causes to be optimistic in our new fiscal year. The Contract Research revenue backlog increased to $33.2 million at September 30, 2017, up from the September 30, 2016 level of $30 million. Additionally, gross profit as a percent of revenue for the Contract Research segment improved to 41% in fiscal year 2017, compared to 38% in fiscal year 2016 as a result of an increase in the sales of commercial products during fiscal year 2017, which carry a stronger profit margin.”
“Xcede Technologies, Inc. (“Xcede”), our majority-owned subsidiary, continues to make great progress in developing its tissue sealant product, the Xcede Patch, and is on track to begin first-in-human trials in 2018,” added Mr. Sulick. “In November 2016, Cook Biotech Inc. committed to manage the Xcede Patch first-in-human clinical study on behalf of Xcede. Xcede is on a development track to complete first-in-human trials within the next 18 months.”
Dynasil earned net income of $1.9 million in 2017 compared to a net income of $0.3 million in 2016. Net income included net losses of approximately $1.4 million and $2.1 million in 2017 and 2016, respectively, associated with research and start-up costs of Xcede. Because Dynasil has voting control of Xcede via its stock ownership, it is required to be included in our consolidated net income for financial reporting purposes. As of September 30, 2017, Dynasil owned 83% of Xcede’s common stock and approximately 61% of Xcede’s outstanding equity.
Conference Call Information
Dynasil will host a conference call for investors and analysts at 5:00 p.m. ET today, December 20, 2017. The call will be hosted by Chairman, CEO and President Peter Sulick and Chief Financial Officer Robert Bowdring. Those who wish to listen to the conference call can go to the event page or visit the Investor Information section of the Company’s website at www.dynasil.com. The call also may be accessed by dialing (888) 346-2613 or (412) 902-4252. For interested individuals unable to join the live conference call, a webcast replay will be available on the Company’s website for one year.
About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets. Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Newton, Massachusetts, with additional operations in Massachusetts, Minnesota, New Jersey, New York and the United Kingdom. More information about the Company is available at www.dynasil.com.
Forward-looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our compliance with the financial covenants under our loan agreements with Middlesex Savings Bank and Massachusetts Capital Resource Company, our expectations regarding results of operations, the commercialization of our technology, including the Xcede patch and our dual mode detectors, the success of efforts to fund Xcede, results of our pre-clinical and planned clinical trials, regulatory approvals, our development of new technologies including at Dynasil Biomedical, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures and the strength of our intellectual property portfolio. These forward-looking statements may be identified by the use of words such as “plans,” “intends,” “may,” “could,” “expect,” “estimate,” “anticipate,” “continue,” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, Xcede’s ability to produce preclinical data sufficient to enable it to initiate clinical studies of hemostatic patch, clinical results of Xcede’s programs which may not support further development, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company’s Annual Report on Form 10-K and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
DYNASIL CORPORATION OF AMERICA AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| September 30, 2017 | September 30, 2016 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 2,415,000 | $ | 2,607,000 | ||||
| Accounts receivable, net | 3,407,000 | 3,502,000 | ||||||
| Costs in excess of billings and unbilled receivables | 1,317,000 | 1,208,000 | ||||||
| Inventories, net of reserves | 4,326,000 | 3,726,000 | ||||||
| Prepaid expenses and other current assets | 973,000 | 1,078,000 | ||||||
| Total current assets | 12,438,000 | 12,121,000 | ||||||
| Property, Plant and Equipment, net | 7,032,000 | 7,223,000 | ||||||
| Other Assets | ||||||||
| Intangibles, net | 987,000 | 1,067,000 | ||||||
| Deferred tax asset, net | 2,642,000 | - | ||||||
| Goodwill | 5,940,000 | 5,898,000 | ||||||
| Security and other deposits | 58,000 | 60,000 | ||||||
| Total other assets | 9,627,000 | 7,025,000 | ||||||
| Total Assets | $ | 29,097,000 | $ | 26,369,000 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities | ||||||||
| Current portion of long-term debt | $ | 2,007,000 | $ | 2,477,000 | ||||
| Capital lease obligations, current | 91,000 | 105,000 | ||||||
| Convertible notes | - | 3,085,000 | ||||||
| Accounts payable | 2,380,000 | 1,627,000 | ||||||
| Deferred revenue | 129,000 | 238,000 | ||||||
| Accrued expenses and other liabilities | 2,667,000 | 2,955,000 | ||||||
| Total current liabilities | 7,274,000 | 10,487,000 | ||||||
| Long-term Liabilities | ||||||||
| Long-term debt, net of current portion | 1,045,000 | 736,000 | ||||||
| Capital lease obligations, net of current portion | 81,000 | 173,000 | ||||||
| Deferred tax liability | 234,000 | 263,000 | ||||||
| Pension and other long-term liabilities | 38,000 | 43,000 | ||||||
| Total long-term liabilities | 1,398,000 | 1,215,000 | ||||||
| Stockholders' Equity | ||||||||
| Dynasil stockholders' equity | 18,971,000 | 14,973,000 | ||||||
| Noncontrolling interest | 1,454,000 | (306,000 | ) | |||||
| Total stockholders' equity | 20,425,000 | 14,667,000 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 29,097,000 | $ | 26,369,000 | ||||
DYNASIL CORPORATION OF AMERICA
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| 2017 | 2016 | |||||||
| Net revenue | $ | 37,284,000 | $ | 43,442,000 | ||||
| Cost of revenue | 23,386,000 | 27,839,000 | ||||||
| Gross profit | 13,898,000 | 15,603,000 | ||||||
| Operating expenses: | ||||||||
| Sales and marketing | 1,152,000 | 1,153,000 | ||||||
| Research and development | 903,000 | 998,000 | ||||||
| General and administrative | 12,365,000 | 12,777,000 | ||||||
| (Gain) loss on sale of assets | 60,000 | (4,000 | ) | |||||
| Total operating expenses | 14,480,000 | 14,924,000 | ||||||
| Income (loss) from operations | (582,000 | ) | 679,000 | |||||
| Interest expense, net | 212,000 | 294,000 | ||||||
| Income (loss) before taxes | (794,000 | ) | 385,000 | |||||
| Income tax (benefit) | (2,741,000 | ) | 51,000 | |||||
| Net income (loss) | 1,947,000 | 334,000 | ||||||
| Less: Net loss attributable to noncontrolling interest | (246,000 | ) | (354,000 | ) | ||||
| Net income (loss) attributable to common stockholders | $ | 2,193,000 | $ | 688,000 | ||||
| Net income (loss) | $ | 1,947,000 | $ | 334,000 | ||||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation | 160,000 | (809,000 | ) | |||||
| Total comprehensive income (loss) | 2,107,000 | (475,000 | ) | |||||
| Less: comprehensive income (loss) attributable to noncontrolling interest | (246,000 | ) | (354,000 | ) | ||||
| Total comprehensive income (loss) attributable to common stockholders | $ | 2,353,000 | $ | (121,000 | ) | |||
| Basic net income (loss) per common share | $ | 0.13 | $ | 0.04 | ||||
| Diluted net income (loss) per common share | $ | 0.13 | $ | 0.04 | ||||
| Weighted average shares outstanding | ||||||||
| Basic | 16,909,412 | 16,657,563 | ||||||
| Diluted | 16,911,504 | 16,693,501 | ||||||